{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li N"],"funding":["NCATS NIH HHS","NIH Clinical Center","NCI NIH HHS","National Institutes of Health"],"pagination":["1240"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7393232"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["<b>Background:</b> The longitudinal monitoring of actionable oncogenes in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) is crucial for clinicians to evaluate current therapeutic response and adjust therapeutic strategies. Saliva-based electric field-induced release and measurement (EFIRM) is liquid biopsy platform to that can directly detect mutation genes with a small volume of samples. Herein, we compared the effectiveness of longitudinal monitoring for the combination of epidermal growth factor receptor (<i>EGFR)</i> and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (<i>PIK3CA)</i> mutations between saliva-based EFIRM and plasma-based platforms (ddPCR and NGS) in two advanced NSCLC patients undergoing the treatment with osimertinib before "],"journal":["Frontiers in oncology"],"pubmed_title":["Longitudinal Monitoring of <i>EGFR</i> and <i>PIK3CA</i> Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports."],"pmcid":["PMC7393232"],"funding_grant_id":["U01 CA233370","UH3 CA206126","UH2 CA206126","UH3 TR000923","R21 CA239052"],"pubmed_authors":["Kim C","Ye L","Wong DTW","Guha U","Li F","Wei F","Chia D","Li N","Cheng J"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal Monitoring of <i>EGFR</i> and <i>PIK3CA</i> Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports.","description":"<b>Background:</b> The longitudinal monitoring of actionable oncogenes in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) is crucial for clinicians to evaluate current therapeutic response and adjust therapeutic strategies. Saliva-based electric field-induced release and measurement (EFIRM) is liquid biopsy platform to that can directly detect mutation genes with a small volume of samples. Herein, we compared the effectiveness of longitudinal monitoring for the combination of epidermal growth factor receptor (<i>EGFR)</i> and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (<i>PIK3CA)</i> mutations between saliva-based EFIRM and plasma-based platforms (ddPCR and NGS) in two advanced NSCLC patients undergoing the treatment with osimertinib before ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2026-05-02T15:31:13.69Z","creation":"2020-08-20T07:18:33Z"},"accession":"S-EPMC7393232","cross_references":{"pubmed":["32793495"],"doi":["10.3389/fonc.2020.01240"]}}